|
US860913A
(en)
|
1906-09-13 |
1907-07-23 |
Max Haeberlein |
Oil-brake for speed-governors.
|
|
GB1164828A
(en)
|
1965-10-23 |
1969-09-24 |
Robins Co Inc A H |
3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
|
|
US3781300A
(en)
|
1969-06-09 |
1973-12-25 |
American Home Prod |
Method of producing 2-halo-3-substituted indoles
|
|
US3594391A
(en)
|
1969-06-09 |
1971-07-20 |
American Home Prod |
2-halo-3-substituted indoles
|
|
ZA795239B
(en)
|
1978-10-12 |
1980-11-26 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
US5340838A
(en)
|
1990-05-04 |
1994-08-23 |
Eli Lilly And Company |
Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
|
|
CA2102303A1
(en)
|
1991-06-19 |
1992-12-20 |
Roy Allen Johnson |
Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
|
|
JP3361836B2
(ja)
*
|
1991-07-04 |
2003-01-07 |
三共株式会社 |
アミノ酸誘導体
|
|
FR2691145A1
(fr)
|
1992-05-18 |
1993-11-19 |
Inst Nat Sante Rech Med |
Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
|
|
GB9226532D0
(en)
|
1992-12-21 |
1993-02-17 |
Smithkline Beecham Plc |
Compounds
|
|
WO1995006638A1
(en)
|
1993-09-01 |
1995-03-09 |
Allelix Biopharmaceuticals Inc. |
Tryptamine analogs with 5-ht1d selectivity
|
|
JPH09510216A
(ja)
|
1994-03-11 |
1997-10-14 |
イーライ・リリー・アンド・カンパニー |
５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法
|
|
US6025374A
(en)
|
1994-12-06 |
2000-02-15 |
Merck Sharp & Dohme, Ltd. |
Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
|
|
EP0821957A3
(en)
|
1996-08-01 |
1998-04-22 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
|
|
US6500456B1
(en)
|
1997-10-03 |
2002-12-31 |
Warner-Lambert Company |
Compressed nitroglycerin tablet and its method of manufacture
|
|
US6436950B1
(en)
|
1998-08-14 |
2002-08-20 |
Nastech Pharmaceutical Company, Inc. |
Nasal delivery of apomorphine
|
|
NZ510988A
(en)
|
1998-10-07 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
|
|
US6403808B1
(en)
|
1999-12-10 |
2002-06-11 |
Virginia Commonwealth University |
Selective 5-HT6 receptor ligands
|
|
US6488648B1
(en)
|
1999-01-14 |
2002-12-03 |
Teijin Limited |
Device for feeding a powder in a predetermined amount and method thereof
|
|
GB0114272D0
(en)
|
2001-06-12 |
2001-08-01 |
Optinose As |
Nasal delivery device
|
|
GB0121568D0
(en)
|
2001-09-06 |
2001-10-24 |
Optinose As |
Nasal delivery device
|
|
NZ514442A
(en)
|
1999-03-03 |
2003-08-29 |
Optinose As |
Nasal delivery device
|
|
HUP0202143A3
(en)
|
1999-07-28 |
2003-12-29 |
Ortho Mcneil Pharm Inc |
Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
|
|
DE10007948A1
(de)
|
2000-02-22 |
2001-09-06 |
Wella Ag |
Mittel zur Färbung von Fasern
|
|
US20020052370A1
(en)
|
2000-07-06 |
2002-05-02 |
Barber Christopher Gordon |
Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
|
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
|
GB0019715D0
(en)
|
2000-08-10 |
2000-09-27 |
Pa Consulting Services |
Device for delivering physiologically active agent in powdered form
|
|
ZA200306564B
(en)
|
2001-02-26 |
2004-10-15 |
Optinose As |
Nasal devices.
|
|
ES2566056T3
(es)
|
2001-03-29 |
2016-04-08 |
Eli Lilly And Company |
N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
|
|
ITRM20010356A1
(it)
|
2001-06-21 |
2002-12-23 |
Sigma Tau Ind Farmaceuti |
"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
|
|
US20050245594A1
(en)
|
2001-06-29 |
2005-11-03 |
Sutter Diane E |
Dermal delivery of anti-pain agents and methods useful thereof
|
|
AU2002340083A1
(en)
|
2001-09-28 |
2003-04-07 |
Kurve Technology, Inc |
Nasal nebulizer
|
|
EP1336602A1
(en)
*
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
GB0207422D0
(en)
|
2002-03-28 |
2002-05-08 |
Optinose As |
Nasal devices
|
|
GB0207817D0
(en)
|
2002-04-04 |
2002-05-15 |
Optinose As |
Nasal devices
|
|
GB0209494D0
(en)
|
2002-04-25 |
2002-06-05 |
Optinose As |
Nasal devices
|
|
US20040127409A1
(en)
|
2002-11-07 |
2004-07-01 |
Milkhaus Laboratory, Inc. |
Method of treatment of psychological conditions by administration of nerve growth factor
|
|
US20050152858A1
(en)
|
2003-07-11 |
2005-07-14 |
Isp Investments Inc. |
Solubilizing agents for active or functional organic compounds
|
|
AU2005244770A1
(en)
*
|
2004-04-26 |
2005-12-01 |
Vanderbilt University |
Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
|
|
WO2006099416A1
(en)
*
|
2005-03-11 |
2006-09-21 |
Nitromed, Inc. |
2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
|
WO2006105615A1
(en)
|
2005-04-08 |
2006-10-12 |
Ozpharma Pty Ltd |
Buccal delivery system
|
|
EP1962837A4
(en)
|
2005-12-20 |
2011-12-14 |
Teikoku Pharma Usa Inc |
METHODS OF PERCUTANEOUS DELIVERY OF INDOLIC SEROTONIN RECEPTOR AGONIST AND PERCUTANEOUS COMPOSITIONS FOR USE THEREIN
|
|
US7429575B2
(en)
|
2006-01-10 |
2008-09-30 |
Yu Ruey J |
N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
|
|
CA2642685A1
(en)
|
2006-02-17 |
2007-08-30 |
Gilead Colorado, Inc. |
Antihypertensive therapy
|
|
HRP20120479T1
(hr)
|
2006-06-28 |
2012-07-31 |
Chelsea@Therapeutics@Inc |
Farmaceutski sastavi sa droksidopom
|
|
US20080248511A1
(en)
|
2007-03-26 |
2008-10-09 |
Promega Corporation |
Methods to quench light from optical reactions
|
|
CA2686994A1
(en)
|
2007-05-11 |
2008-11-20 |
Mpex Pharmaceuticals, Inc. |
Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
EP2209380A4
(en)
|
2007-10-09 |
2011-09-14 |
Mark T Hamann |
METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
|
|
EP2240022B1
(en)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Bilayered tablets comprising oxycodone and promethazine
|
|
BRPI0919920A2
(pt)
|
2008-10-22 |
2016-02-16 |
Acucela Inc |
compostos para tratamento de doenças e desordens oftálmicas
|
|
AU2010251930A1
(en)
|
2009-05-27 |
2011-11-24 |
Universite Libre De Bruxelles |
3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
|
|
WO2010151258A1
(en)
|
2009-06-24 |
2010-12-29 |
The Board Of Regents Of The University Of Oklahoma |
Methods of treating psychological conditions
|
|
US8912220B2
(en)
|
2009-08-10 |
2014-12-16 |
Galenea Pharmaceuticals |
Compounds and methods of use thereof
|
|
WO2011041870A1
(en)
*
|
2009-10-07 |
2011-04-14 |
Nitrogenix Inc. |
Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
EP2418196A1
(en)
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
|
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
|
WO2013142770A1
(en)
|
2012-03-23 |
2013-09-26 |
Codexis, Inc. |
Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
|
|
EP2830599B1
(en)
|
2012-03-29 |
2018-08-15 |
Therabiome, Llc |
Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
|
|
US9580400B2
(en)
*
|
2013-02-26 |
2017-02-28 |
Northeastern University |
Cannabinergic nitrate esters and related analogs
|
|
EP2796139A1
(en)
|
2013-04-26 |
2014-10-29 |
AOP Orphan Pharmaceuticals AG |
Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
|
|
US9549942B2
(en)
|
2013-07-15 |
2017-01-24 |
Research & Business Foundation Sungkyunkwan University |
Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins
|
|
TWI659017B
(zh)
|
2013-11-24 |
2019-05-11 |
臺北醫學大學 |
吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
|
|
EP3110419A4
(en)
|
2014-02-25 |
2017-07-26 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of complement mediated disorders
|
|
GB201409516D0
(en)
|
2014-05-29 |
2014-07-16 |
Randox Lab Ltd |
Immunoassay for compounds of the NBOMe family
|
|
US20220079881A1
(en)
|
2016-03-03 |
2022-03-17 |
Ctt Pharma Inc. |
Orally Administrable Composition
|
|
EP3519816A4
(en)
|
2016-09-29 |
2020-05-06 |
The Regents of the University of California |
CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
|
|
WO2018081456A1
(en)
|
2016-10-26 |
2018-05-03 |
University Of Florida Research Foundation, Incorporated |
Highly active self-sufficient nitration biocatalysts
|
|
WO2018094106A2
(en)
|
2016-11-16 |
2018-05-24 |
University Of South Florida |
ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
|
|
WO2018094005A1
(en)
|
2016-11-16 |
2018-05-24 |
The General Hospital Corporation |
Myeloperoxidase imaging agents
|
|
WO2018106907A1
(en)
|
2016-12-08 |
2018-06-14 |
Novatarg, Inc. |
Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
|
|
JP7273731B2
(ja)
|
2017-02-09 |
2023-05-15 |
カームテック、エルエルシー |
シロシビン誘導体を含む組成物及び方法
|
|
US11974984B2
(en)
|
2017-02-09 |
2024-05-07 |
Caamtech, Inc. |
Compositions and methods comprising a combination of serotonergic drugs
|
|
US20200147038A1
(en)
|
2017-04-20 |
2020-05-14 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
JP7403050B2
(ja)
|
2017-08-28 |
2023-12-22 |
ユニバーシティ オブ メリーランド ボルチモア |
気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
|
|
GB201715919D0
(en)
|
2017-09-29 |
2017-11-15 |
Gw Res Ltd |
use of cannabinoids in the treatment of epilepsy
|
|
US11723894B2
(en)
*
|
2017-10-26 |
2023-08-15 |
Terran Biosciences, Inc. |
Combination product for the treatment of neurological and/or psychiatric disorders
|
|
WO2019099402A1
(en)
|
2017-11-14 |
2019-05-23 |
Rutgers, The State University Of New Jersey |
Therapeutic compounds and methods to treat infection
|
|
JP2021514682A
(ja)
|
2018-03-08 |
2021-06-17 |
ニュー アトラス バイオテクノロジーズ エルエルシー |
トリプタミンの生産方法
|
|
CN118121577A
(zh)
|
2018-05-04 |
2024-06-04 |
感知神经科学公司 |
治疗物质滥用的方法
|
|
EP3841085B1
(en)
|
2018-08-22 |
2026-05-06 |
University Of Technology Sydney |
Nbome test
|
|
CN112912016A
(zh)
|
2018-11-07 |
2021-06-04 |
巴克斯特国际公司 |
双止回阀单手涂敷器
|
|
MX2021009037A
(es)
|
2019-01-30 |
2021-10-13 |
Diamond Therapeutics Inc |
Composiciones y metodos para el manejo de trastornos.
|
|
HUE066828T2
(hu)
|
2019-02-22 |
2024-09-28 |
Gh Res Ireland Limited |
5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
|
|
DK3927338T3
(da)
|
2019-02-22 |
2025-01-06 |
Gh Res Ireland Limited |
Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
|
|
WO2020176597A1
(en)
|
2019-02-27 |
2020-09-03 |
The Regents Of The University Of California |
N-substituted indoles and other heterocycles for treating brain disorders
|
|
US12616706B2
(en)
*
|
2019-03-07 |
2026-05-05 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
KR20220008824A
(ko)
|
2019-04-17 |
2022-01-21 |
컴퍼스 패쓰파인더 리미티드 |
실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
|
|
GB201907871D0
(en)
|
2019-06-03 |
2019-07-17 |
Small Pharma Ltd |
Therapeutic compositions
|
|
WO2021003467A1
(en)
|
2019-07-04 |
2021-01-07 |
Sw Holdings, Inc. |
Metered dosing compositions and methods of use of psychedelic compounds
|
|
US20210015738A1
(en)
|
2019-07-17 |
2021-01-21 |
Concept Matrix Solutions |
Oral dissolvable film containing psychedelic compound
|
|
WO2021041407A1
(en)
*
|
2019-08-25 |
2021-03-04 |
Caamtech Llc |
Alkyl quarternary ammonium tryptamines and their therapeutic uses
|
|
HRP20220797T1
(hr)
|
2019-11-07 |
2022-10-14 |
Small Pharma Ltd |
Spojevi
|
|
US11660305B2
(en)
|
2019-11-19 |
2023-05-30 |
Turtle Bear Holdings, Llc |
Tryptamine compositions for enhancing neurite outgrowth
|
|
MX2022009527A
(es)
|
2020-02-04 |
2022-11-16 |
Mindset Pharma Inc |
Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
|
|
US20210236523A1
(en)
|
2020-02-05 |
2021-08-05 |
Yale University |
Psychedelic treatment for headache disorders
|
|
LT4084791T
(lt)
|
2020-02-18 |
2025-02-25 |
Gilgamesh Pharmaceuticals, Inc. |
Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
|
|
AU2021237640B2
(en)
|
2020-03-19 |
2024-01-04 |
Caamtech, Inc. |
Crystalline psilacetin derivatives
|
|
US11358934B2
(en)
|
2020-03-23 |
2022-06-14 |
Caamtech, Inc. |
Crystalline forms of psilacetin
|
|
US11332441B2
(en)
|
2020-03-23 |
2022-05-17 |
Caamtech, Inc. |
Crystalline N-methyl tryptamine derivatives
|
|
CA3173048A1
(en)
|
2020-04-16 |
2021-10-21 |
Fotios M. Plakogiannis |
Transdermal micro-dosing delivery of psychedelics derivatives
|
|
US20210322306A1
(en)
|
2020-04-21 |
2021-10-21 |
Cure Pharmaceutical Holding Corp. |
Oral dissolvable film with high load of polymeric binder
|
|
WO2021226041A1
(en)
|
2020-05-04 |
2021-11-11 |
Caamtech, Inc. |
Crystalline dimethyl tryptamine analogues
|
|
IL297861A
(en)
|
2020-05-08 |
2023-01-01 |
Psilera Inc |
Novel compositions of matter and pharmaceutical compositions
|
|
IL312785B2
(en)
|
2020-05-19 |
2026-06-01 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use
|
|
US12042564B2
(en)
|
2020-06-02 |
2024-07-23 |
Cybin Uk Ltd |
Therapeutic solid dosage forms
|
|
WO2021116503A2
(en)
*
|
2020-06-02 |
2021-06-17 |
Small Pharma Ltd |
Deuterated compounds
|
|
BR112022025306A2
(pt)
|
2020-06-12 |
2023-02-28 |
Beckley Psytech Ltd |
Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
|
|
EP4167992A1
(en)
|
2020-06-22 |
2023-04-26 |
University of Zürich |
Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
|
|
DK4172145T3
(da)
|
2020-06-30 |
2026-07-20 |
Reunion Neuroscience Inc |
Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
|
|
US11406619B2
(en)
|
2020-08-28 |
2022-08-09 |
Small Pharma Ltd |
Injectable formulations
|
|
EP4208457A1
(en)
|
2020-09-04 |
2023-07-12 |
Gilgamesh Pharmaceuticals, Inc. |
Azetidinyl tryptamines and methods of treating psychiatric disorders
|
|
CA3192617A1
(en)
|
2020-09-20 |
2022-03-24 |
Matthew BAGGOTT |
Advantageous tryptamine compositions for mental disorders or enhancement
|
|
WO2022082058A1
(en)
|
2020-10-16 |
2022-04-21 |
Eleusis Therapeutics Us, Inc. |
Method of treatment by tryptamine alkaloids
|
|
EP4247340A4
(en)
|
2020-11-18 |
2024-10-02 |
Bexson Biomedical, Inc. |
COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
|
|
WO2022123232A1
(en)
|
2020-12-07 |
2022-06-16 |
Beckley Psytech Limited |
Pharmaceutical composition comprising psilocybin or its polymorphs
|
|
EP4274831A4
(en)
|
2021-01-11 |
2024-05-01 |
Caamtech, Inc. |
Quaternary tryptamines and their therapeutic uses
|
|
WO2022160056A1
(en)
|
2021-01-29 |
2022-08-04 |
Algernon Pharmaceuticals Inc. |
Dmt salts and their use to treat brain injury
|
|
US20240189331A1
(en)
|
2021-02-12 |
2024-06-13 |
Intelgenx Corp. |
Novel tryptamine oral film formulation
|
|
US20220273628A1
(en)
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
CN117177959A
(zh)
|
2021-03-18 |
2023-12-05 |
赛本爱尔兰有限公司 |
裸头草碱类似物、盐、组合物和使用方法
|
|
AU2022239825C1
(en)
|
2021-03-18 |
2026-08-13 |
Cybin Irl Limited |
Psilocybin analogs, salts, compositions, and methods of use
|
|
US20230136824A1
(en)
|
2021-04-26 |
2023-05-04 |
ATAI Life Sciences AG |
N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
|
|
CA3216889A1
(en)
|
2021-04-26 |
2022-11-03 |
Glenn Short |
Novel n,n-dimethyltryptamine compositions and methods
|
|
EP4333979A4
(en)
|
2021-05-03 |
2025-01-15 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
WO2022235514A1
(en)
|
2021-05-04 |
2022-11-10 |
Mind Medicine, Inc. |
Liposome delivery of psychedelics
|
|
EP4792879A2
(en)
|
2021-05-17 |
2026-08-19 |
Cybin IRL Limited |
Formulations of psilocybin
|
|
KR20240013170A
(ko)
|
2021-05-25 |
2024-01-30 |
아타이 테라퓨틱스, 인크. |
신규 n,n-디메틸트립타민 염 및 결정질 염 형태
|
|
WO2022246572A1
(en)
|
2021-05-26 |
2022-12-01 |
Mindset Pharma Inc. |
Hallucinogen-fatty acid combination
|
|
IL309210A
(en)
|
2021-06-09 |
2024-02-01 |
Atai Therapeutics Inc |
Parent drugs and conjugates of dimethyltryptamine
|
|
WO2023283386A2
(en)
|
2021-07-07 |
2023-01-12 |
Arcadia Medicine, Inc. |
Safer psychoactive compositions
|
|
EP4137131A1
(en)
|
2021-08-17 |
2023-02-22 |
Centre National de la Recherche Scientifique (CNRS) |
Novel serotonin analogues and their uses for treating iron-associated disorders
|
|
AU2022342266B2
(en)
|
2021-09-08 |
2026-03-26 |
Cybin Irl Limited |
Combination drug therapies
|
|
US20230310374A1
(en)
|
2021-09-30 |
2023-10-05 |
ATAI Life Sciences AG |
Compositions and methods for treating headache or facial pain
|
|
EP4408412A4
(en)
|
2021-09-30 |
2025-07-16 |
ATAI Life Sciences AG |
COMPOSITIONS AND METHODS FOR TREATING HEADACHES
|
|
WO2023076135A1
(en)
|
2021-10-29 |
2023-05-04 |
Psilera Inc. |
N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
|
|
EP4423062A4
(en)
|
2021-10-29 |
2025-08-27 |
Psilera Inc |
MODIFIED INDOLE COMPOUNDS
|
|
AU2022413759A1
(en)
|
2021-12-13 |
2024-06-27 |
Beckley Psytech Limited |
Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
|
|
CA3244229A1
(en)
|
2021-12-24 |
2023-06-29 |
Psylo Pty Ltd |
COMPOUNDS
|
|
JP2025501141A
(ja)
|
2021-12-24 |
2025-01-17 |
サイロ プロプリエタリー リミテッド |
化合物
|
|
US11912680B2
(en)
*
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
|
CA3238440A1
(en)
|
2021-12-30 |
2023-07-06 |
Atai Therapeutics, Inc. |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
EP4584247A2
(en)
|
2022-09-06 |
2025-07-16 |
ATAI Therapeutics, Inc. |
Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors
|
|
EP4608395A2
(en)
|
2022-10-26 |
2025-09-03 |
ATAI Therapeutics, Inc. |
N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
|
|
WO2024118767A2
(en)
|
2022-11-29 |
2024-06-06 |
Caamtech, Inc. |
Tryptamine derivatives
|
|
TW202430149A
(zh)
|
2022-12-01 |
2024-08-01 |
美商雅特益醫療公司 |
Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法
|
|
EP4633625A2
(en)
|
2022-12-15 |
2025-10-22 |
ATAI Therapeutics, Inc. |
Prodrugs of dimethyltryptamine and derivatives thereof
|
|
EP4704833A2
(en)
|
2023-04-27 |
2026-03-11 |
ATAI Therapeutics, Inc. |
Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
|
|
JP2026518190A
(ja)
|
2023-05-24 |
2026-06-04 |
サイレラ インコーポレイテッド |
トリプタミン誘導体を含む製剤およびそれらの使用
|
|
US12246005B2
(en)
|
2023-06-13 |
2025-03-11 |
Beckley Psytech Limited |
5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
|
|
EP4746873A1
(en)
|
2023-07-19 |
2026-05-27 |
ATAI Therapeutics, Inc. |
Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same
|
|
EP4750467A1
(en)
|
2023-07-25 |
2026-06-03 |
ATAI Therapeutics, Inc. |
Compositions for limiting sympathomimetic effects of psychedelic therapeutics
|
|
EP4773958A1
(en)
|
2023-09-08 |
2026-07-15 |
ATAI Therapeutics, Inc. |
Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
|
|
EP4788322A1
(en)
|
2023-10-02 |
2026-08-12 |
ATAI Therapeutics, Inc. |
N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
|
|
WO2025137581A1
(en)
|
2023-12-21 |
2025-06-26 |
Atai Therapeutics, Inc. |
Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions
|
|
WO2025170990A1
(en)
|
2024-02-06 |
2025-08-14 |
Atai Therapeutics, Inc. |
Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
|